RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
$65.27M
Dr. Brian Russell Wong M.D., Ph.D.
94.00
South San Francisco, CA
Oct 31, 2019
-0.60
$-3.13
3.25
13.46
-14,746.18%
-5.52
2.61
729.51
13.30
-42.82%
-44.24%
Similar stocks (14)
Arvinas, Inc.
ARVN
Relay Therapeutics, Inc.
RLAY
Pliant Therapeutics, Inc.
PLRX
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
Eliem Therapeutics, Inc.
ELYM
Black Diamond Therapeutics, Inc.
BDTX
PepGen Inc.
PEPG
Werewolf Therapeutics, Inc.
HOWL
PMV Pharmaceuticals, Inc.
PMVP
Ikena Oncology, Inc.
IKNA
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
HCW Biologics Inc.
HCWB
ETF Exposure (14)
iShares Micro-Cap ETF
IWC
0.01212%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.006%
iShares Biotechnology ETF
IBB
0.00498%
iShares Russell 2000 Value ETF
IWN
0.00369%
ProShares Ultra Nasdaq Biotechnology
BIB
0.001821483712846889%
iShares Russell 2000 ETF
IWM
0.00172%
Dimensional U.S. Targeted Value ETF
DFAT
9.592899999999999e-4%
ProShares Hedge Replication ETF
HDG
2.935210293478857e-4%
Dimensional U.S. Small Cap ETF
DFAS
1.1908e-4%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
9.0e-5%
Dimensional U.S. Core Equity 2 ETF
DFAC
8.372e-5%
Dimensional US Core Equity Market ETF
DFAU
6.691e-5%
iShares Russell 3000 ETF
IWV
6.0e-5%
Dimensional U.S. Equity ETF
DFUS
5.543e-5%
Similar stocks (14)
Arvinas, Inc.
ARVN
Relay Therapeutics, Inc.
RLAY
Pliant Therapeutics, Inc.
PLRX
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
Eliem Therapeutics, Inc.
ELYM
Black Diamond Therapeutics, Inc.
BDTX
PepGen Inc.
PEPG
Werewolf Therapeutics, Inc.
HOWL
PMV Pharmaceuticals, Inc.
PMVP
Ikena Oncology, Inc.
IKNA
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
HCW Biologics Inc.
HCWB
ETF Exposure (14)
iShares Micro-Cap ETF
IWC
0.01212%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.006%
iShares Biotechnology ETF
IBB
0.00498%
iShares Russell 2000 Value ETF
IWN
0.00369%
ProShares Ultra Nasdaq Biotechnology
BIB
0.001821483712846889%
iShares Russell 2000 ETF
IWM
0.00172%
Dimensional U.S. Targeted Value ETF
DFAT
9.592899999999999e-4%
ProShares Hedge Replication ETF
HDG
2.935210293478857e-4%
Dimensional U.S. Small Cap ETF
DFAS
1.1908e-4%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
9.0e-5%
Dimensional U.S. Core Equity 2 ETF
DFAC
8.372e-5%
Dimensional US Core Equity Market ETF
DFAU
6.691e-5%
iShares Russell 3000 ETF
IWV
6.0e-5%
Dimensional U.S. Equity ETF
DFUS
5.543e-5%